Summary
Global Markets Direct’s, ‘Bone Metastasis - Pipeline Review, H1 2016’, provides an overview of the Bone Metastasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bone Metastasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews pipeline therapeutics for Bone Metastasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Metastasis therapeutics and enlists all their major and minor projects
- The report assesses Bone Metastasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Metastasis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ablynx NV
Alethia Biotherapeutics Inc.
Amgen Inc.
Amura Holdings Limited
Bayer AG
Campus Technologies Freiburg GmbH
ChemoCentryx, Inc.
Deciphera Pharmaceuticals, LLC
Oncobiologics, Inc.
Oncodrone BV
Osteologix Holdings Plc
R-Pharm
Sigma-Tau S.p.A.
Taiho Pharmaceutical Co., Ltd.
Terpenoid Therapeutics, Inc.
Thar Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bone Metastasis Overview 10
Therapeutics Development 11
Pipeline Products for Bone Metastasis – Overview 11
Pipeline Products for Bone Metastasis – Comparative Analysis 12
Bone Metastasis – Therapeutics under Development by Companies 13
Bone Metastasis – Therapeutics under Investigation by Universities/Institutes 15
Bone Metastasis – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bone Metastasis – Products under Development by Companies 19
Bone Metastasis – Products under Investigation by Universities/Institutes 20
Bone Metastasis – Companies Involved in Therapeutics Development 21
Ablynx NV 21
Alethia Biotherapeutics Inc. 22
Amgen Inc. 23
Amura Holdings Limited 24
Bayer AG 25
Campus Technologies Freiburg GmbH 26
ChemoCentryx, Inc. 27
Deciphera Pharmaceuticals, LLC 28
Oncobiologics, Inc. 29
Oncodrone BV 30
Osteologix Holdings Plc 31
R-Pharm 32
Sigma-Tau S.p.A. 33
Taiho Pharmaceutical Co., Ltd. 34
Terpenoid Therapeutics, Inc. 35
Thar Pharmaceuticals, Inc. 36
Bone Metastasis – Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
AB-25E9 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ADM-01 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ALX-0141 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AM-3701 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AMG-161 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BKM-1644 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BKM-1740 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CCX-354 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CCX-721 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DCC-3014 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
denosumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
denosumab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LG-1980 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
NBS-101 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OCD-155 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
radium Ra 223 dichloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
roneparstat - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RPH-203 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
RSF-102 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RSF-103 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
TAS-115 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TPH-9 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
vicrostatin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
zoledronic acid - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Bone Metastasis – Recent Pipeline Updates 81
Bone Metastasis - Dormant Projects 100
Bone Metastasis – Discontinued Products 103
Bone Metastasis – Product Development Milestones 104
Featured News & Press Releases 104
Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan 104
Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) 105
Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna 106
Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease 106
Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 107
Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 109
Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 109
Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 110
May 30, 2013: Algeta Announces First Sale Of Xofigo In US 111
Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 112
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114
List of Tables
Number of Products under Development for Bone Metastasis, H1 2016 11
Number of Products under Development for Bone Metastasis – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Bone Metastasis – Pipeline by Ablynx NV, H1 2016 21
Bone Metastasis – Pipeline by Alethia Biotherapeutics Inc., H1 2016 22
Bone Metastasis – Pipeline by Amgen Inc., H1 2016 23
Bone Metastasis – Pipeline by Amura Holdings Limited, H1 2016 24
Bone Metastasis – Pipeline by Bayer AG, H1 2016 25
Bone Metastasis – Pipeline by Campus Technologies Freiburg GmbH, H1 2016 26
Bone Metastasis – Pipeline by ChemoCentryx, Inc., H1 2016 27
Bone Metastasis – Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 28
Bone Metastasis – Pipeline by Oncobiologics, Inc., H1 2016 29
Bone Metastasis – Pipeline by Oncodrone BV , H1 2016 30
Bone Metastasis – Pipeline by Osteologix Holdings Plc, H1 2016 31
Bone Metastasis – Pipeline by R-Pharm, H1 2016 32
Bone Metastasis – Pipeline by Sigma-Tau S.p.A., H1 2016 33
Bone Metastasis – Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 34
Bone Metastasis – Pipeline by Terpenoid Therapeutics, Inc., H1 2016 35
Bone Metastasis – Pipeline by Thar Pharmaceuticals, Inc., H1 2016 36
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Bone Metastasis Therapeutics – Recent Pipeline Updates, H1 2016 81
Bone Metastasis – Dormant Projects, H1 2016 100
Bone Metastasis – Dormant Projects (Contd..1), H1 2016 101
Bone Metastasis – Dormant Projects (Contd..2), H1 2016 102
Bone Metastasis – Discontinued Products, H1 2016 103
List of Figures
Number of Products under Development for Bone Metastasis, H1 2016 11
Number of Products under Development for Bone Metastasis – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Top 10 Targets, H1 2016 38
Number of Products by Stage and Top 10 Targets, H1 2016 38
Number of Products by Top 10 Mechanism of Actions, H1 2016 40
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 40
Number of Products by Routes of Administration, H1 2016 42
Number of Products by Stage and Routes of Administration, H1 2016 42
Number of Products by Top 10 Molecule Types, H1 2016 44
Number of Products by Stage and Top 10 Molecule Types, H1 2016 44
